Pancreatic Cancer Research

ResearcherFujian Medical UniversityActive in the last 2 years

Yan Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2563-255X; OpenAlex author ID A5100322938. Sources: OpenAlex.

Their work

Papers
19 (first author 4, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
50
Papers, trials and grants by year

2016: 3 papers · 2017: none · 2018: none · 2019: none · 2020: 2 papers · 2021: 2 papers · 2022: 9 papers · 2023: 2 papers · 2024: 1 paper

Papers 19

  1. KDM5B promotes SMAD4 loss-driven drug resistance through activating DLG1/YAP to induce lipid accumulation in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41420-024-02020-4↗
  2. METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation. Co-author DOI 10.1038/s41419-023-05715-1↗
  3. Comprehensive bioinformatics analysis reveals the significance of forkhead box family members in pancreatic adenocarcinoma. Co-author DOI 10.18632/aging.204455↗
  4. Remarkable response of BRAF V600E-mutated metastatic pancreatic cancer to BRAF/MEK inhibition: a case report. Last author DOI 10.1093/gastro/goab031↗
  5. The m6A demethylase ALKBH5-mediated upregulation of DDIT4-AS1 maintains pancreatic cancer stemness and suppresses chemosensitivity by activating the mTOR pathw… Co-author DOI 10.1186/s12943-022-01647-0↗
  6. N6-methyladenosine-mediated SH3BP5-AS1 upregulation promotes GEM chemoresistance in pancreatic cancer by activating the Wnt signaling pathway. First author DOI 10.1186/s13062-022-00347-5↗
  7. N6-methyladenosine-mediated CELF2 regulates CD44 alternative splicing affecting tumorigenesis via ERAD pathway in pancreatic cancer. First author DOI 10.1186/s13578-022-00844-0↗
  8. Rosiglitazone disrupts pancreatic ductal adenocarcinoma progression by activating the tumor suppressor ESE3/EHF. Co-author DOI 10.20892/j.issn.2095-3941.2022.0299↗
  9. N6-methyladenosine-mediated SH3BP5-AS1 upregulation promotes GEM chemoresistance in pancreatic cancer by competitively sponging miR-139-5p and activating the W… First author DOI 10.21203/rs.3.rs-1242747/v1↗
  10. Clinical Significance and Bioinformatics Analysis of SMC Family in Pancreatic Adenocarcinoma Co-author DOI 10.21203/rs.3.rs-1415881/v1↗
  11. Classification and Prognosis Analysis of Pancreatic Cancer Based on DNA Methylation Profile and Clinical Information. Co-author DOI 10.3390/genes13101913↗
  12. Inhibition of glutathione metabolism can limit the development of pancreatic cancer. Co-author DOI 10.4252/wjsc.v14.i5.362↗
  13. SIRT1 coordinates with the CRL4B complex to regulate pancreatic cancer stem cells to promote tumorigenesis. Last author DOI 10.1038/s41418-021-00821-z↗
  14. [CRL4B complex promotes the development of pancreatic cancer by inhibiting secreted frizzled related protein 1]. Last author DOI 10.3760/cma.j.cn112152-20210108-00030↗
  15. MGMT expression affects the gemcitabine resistance of pancreatic cancer cells. First author DOI 10.1016/j.lfs.2020.118148↗
  16. Construction of an RNA-Binding Protein-Related Prognostic Model for Pancreatic Adenocarcinoma Based on TCGA and GTEx Databases. Co-author DOI 10.3389/fgene.2020.610350↗
  17. Polyplex-mediated inhibition of chemokine receptor CXCR4 and chromatin-remodeling enzyme NCOA3 impedes pancreatic cancer progression and metastasis. Co-author DOI 10.1016/j.biomaterials.2016.05.042↗
  18. Oncogenic Functions of Gli1 in Pancreatic Adenocarcinoma Are Supported by Its PRMT1-Mediated Methylation. Co-author DOI 10.1158/0008-5472.can-16-0715↗
  19. Celecoxib suppresses fibroblast growth factor-2 expression in pancreatic ductal adenocarcinoma PANC-1 cells. Co-author DOI 10.3892/or.2016.4924↗

Closest collaborators

The 25 strongest of 50 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shihui Lai · 5 shared papers, 2022–2023 · strength 0.86
  2. Shangeng Weng · 4 shared papers, 2022–2023 · strength 0.70
  3. Xiang Zhang · 4 shared papers, 2022–2023 · strength 0.70
  4. Hongquan Wang · 3 shared papers, 2022–2024 · strength 0.60
  5. Chengjie Lin · 3 shared papers, 2022–2023 · strength 0.52
  6. Liang Wang · 3 shared papers, 2022 · strength 0.51
  7. Mingxu Li · 2 shared papers, 2022–2023 · strength 0.38
  8. Zhong Wang · 2 shared papers, 2022–2023 · strength 0.38
  9. Shuai Leng · 2 shared papers, 2021 · strength 0.34
  10. Hong‐Shuai Li · 1 shared paper, 2022 · strength 0.26
  11. Bo Tang · 1 shared paper, 2022 · strength 0.22
  12. Yue Chen · 1 shared paper, 2021 · strength 0.22
  13. Yumin Wang · 1 shared paper, 2024 · strength 0.22
  14. Bo Tang · 1 shared paper, 2024 · strength 0.22
  15. Wei Hu · 1 shared paper, 2023 · strength 0.20
  16. Zhenyun Guo · 1 shared paper, 2023 · strength 0.19
  17. Yue Huang · 1 shared paper, 2023 · strength 0.19
  18. Zhiqiang Chang · 1 shared paper, 2022 · strength 0.19
  19. Xin Li · 1 shared paper, 2022 · strength 0.19
  20. Haoran Fei · 1 shared paper, 2022 · strength 0.17
  21. Chengjie Lin · 1 shared paper, 2022 · strength 0.17
  22. Wei Wang · 1 shared paper, 2022 · strength 0.17
  23. Peiyuan Cai · 1 shared paper, 2022 · strength 0.17
  24. Yi Zhang · 1 shared paper, 2022 · strength 0.16
  25. Xiaomeng Liu · 1 shared paper, 2022 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.